Editas Q3 net loss narrows to $25.1M; preclinical EDIT-401 shows >90% LDL-C reduction; cash runway extended to Q3 2027

Editas Medicine, Inc.

2025-Q3 EPS reported -$1.80 vs consensus -$0.30 ▼ miss (-495.6%)

Net loss of $25.1M ($0.28/sh) vs $62.1M ($0.75/sh) in Q3 2024; collaboration revenue rose to $7.5M from $0.1M on BMS milestone.
R&D expenses fell 58% to $19.8M; G&A expenses fell 32% to $12.3M, both reflecting reni-cel program discontinuation.
Cash & securities $165.6M at Sept. 30; $17.8M raised via ATM in Q3; runway extended into Q3 2027, enabling EDIT-401 progression.
Preclinical data: single dose of EDIT-401 achieved ≥90% LDL-C reduction in NHPs within 48 hours; durability shown in 3-month mouse study.
On track to file IND/CTA for EDIT-401 by mid-2026; initial human proof-of-concept data expected by year-end 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.